Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief.

However, the rebate game played by drug manufacturers and pharmacy benefit managers in the U.S. limits optimal biosimilar competition. As a result, U.S. patient out-of-pocket costs are too high.

Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making ...

Biosimilar companies are poised to launch cheaper ... In the UK, intravenous trastuzumab is used mainly as part of the combination with Perjeta and chemotherapy in breast cancer, and in metastatic ...

The case centers around a patent infringement suit filed by the Swiss against Zydus, taking objection to the production of 'Sigrima' . It alleged that the product was a biosimilar of the original ...

The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs. That was certainly one of the ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

The European Medicines Agency (EMA) has accepted Alvotech and Advanz Pharma’s marketing authorization application for AVT05, a biosimilar to Johnson & Johnson’s biologic Simponi (golimumab), which is ...

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development ...